Latest stories on CADL
Candel Therapeutics Adds Independent Director to Board
TipRanks55 · neutralgeneral
Candel Therapeutics, Inc. (CADL) files 8-K
SEC 8-K50 · neutralgeneral
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
Business Insider56 · neutralgeneral
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
GlobeNewswire63 · neutralgeneral
Candel Therapeutics, Inc. (CADL) files 8-K
SEC 8-K50 · neutralgeneral
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Candel Therapeutics to Present at September Investor Conferences
GlobeNewswire56 · neutralgeneral
Candel Therapeutics to Present at September Investor Conferences
Business Insider56 · neutralgeneral
Freedom Broker raises Candel Therapeutics stock price target on trial progress
Investing.com Analyst Ratings63 · neutralanalyst
Candel Therapeutics price target raised to $12 from $9 at BofA
The Fly61 · neutralanalyst
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
Stocktwits News67 · bullishproduct/pr
Candel Therapeutics, Inc. (CADL) files 8-K
SEC 8-K50 · neutralgeneral
Candel Therapeutics GAAP EPS of -$0.52 misses by $0.29
Seeking Alpha34 · bearishearnings
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire56 · neutralearnings
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Business Insider56 · neutralproduct/pr
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity
Stocktwits News63 · neutralproduct/pr
Candel Therapeutics: Getting Closer, And Building Out More Paths
Seeking Alpha67 · bullishproduct/pr
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
Business Insider63 · neutralproduct/pr
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
Business Insider56 · neutralgeneral
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential
Seeking Alpha67 · bullishproduct/pr
Candel Therapeutics Awards Inducement Options as Clinical Pipeline Gains FDA Momentum
MarketChameleon58 · neutralgeneral
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CADL Stock News
StockTitan50 · neutralgeneral
Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug
Morningstar63 · neutralproduct/pr